ARK Genomic Revolution ETF vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? ARK Genomic Revolution ETF trades at $44.39, while Vanguard Dividend Appreciation Index Fund ETF trades at $245.81. Which is the better fit depends on your goals.
| ARKG | VIG | |
|---|---|---|
Sector | Sector/Thematic | — |
52-Week High | $44.55 | $245.79 |
52-Week Low | $24.02 | $208.67 |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VIG trades at $245.92, up 0.05% on the day, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on dividend growth stocks like Broadcom, offering a 1.5% yield with a 20-year dividend growth streak. Recent news highlights its role in retirement income strategies amid Social Security adjustments.
Outlook remains positive for long-term investors seeking stable dividend growth, though high RSI levels suggest near-term consolidation risks. Competition with higher-yield ETFs and market volatility pose challenges, but institutional interest and consistent methodology support resilience.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →